1. Original Article: Non–Small Cell Lung Cancer - First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Issue 3 (March 2016) Authors: Schuler, Martin; Wu, Yi‐Long; Hirsh, Vera; O'Byrne, Kenneth; Yamamoto, Nobuyuki; Mok, Tony; Popat, Sanjay; Sequist, Lecia V.; Massey, Dan; Zazulina, Victoria; Yang, James C.‐H. Journal: Journal of thoracic oncology Issue: Volume 11:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. (July 2019) Authors: Schuler, Martin; Paz-Ares, Luis; Sequist, Lecia V.; Hirsh, Vera; Lee, Ki Hyeong; Wu, Yi-Long; Lu, Shun; Zhou, Caicun; Feng, Jifeng; Ellis, Stuart H.; Samuelsen, Carl H.; Tang, Wenbo; Märten, Angela; Ehrnrooth, Eva; Park, Keunchil; Yang, James Chih-Hsin Journal: Lung cancer Issue: Volume 133(2019) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. Issue 1 (December 2018) Authors: Hammoud, Mohamad; Yosef, Hesham; Lechtonen, Tatjana; Aljakouch, Karim; Schuler, Martin; Alsaidi, Wissam; Daho, Ibrahim; Maghnouj, Abdelouahid; Hahn, Stephan; El-Mashtoly, Samir; Gerwert, Klaus Journal: Scientific reports Issue: Volume 8:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The lipid metabolism in thraustochytrids. (October 2019) Authors: Morabito, Christian; Bournaud, Caroline; Maës, Cécile; Schuler, Martin; Aiese Cigliano, Riccardo; Dellero, Younès; Maréchal, Eric; Amato, Alberto; Rébeillé, Fabrice Journal: Progress in lipid research Issue: Volume 76(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. (30th April 2020) Authors: Welt, Anja; Wiesweg, Marcel; Theurer, Sarah; Abenhardt, Wolfgang; Groschek, Matthias; Müller, Lothar; Schröder, Jan; Tewes, Mitra; Chiabudini, Marco; Potthoff, Karin; Bankfalvi, Agnes; Marschner, Norbert; Schuler, Martin; Breitenbücher, Frank Journal: Cancer medicine Issue: Volume 9:Number 13(2020) Page Start: 4527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Issue 1 (25th May 2020) Authors: Bilecz, Agnes; Stockhammer, Paul; Theegarten, Dirk; Kern, Izidor; Jakopovic, Marko; Samarzija, Miroslav; Klikovits, Thomas; Hoda, Mir A; Döme, Balázs; Oberndorfer, Felicitas; Muellauer, Leonhard; Fillinger, János; Kovács, Ildikó; Pirker, Christine; Schuler, Martin; Plönes, Till; Aigner, Clemens; ... Journal: Histopathology Issue: Volume 77:Issue 1(2020) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The zoospores of the thraustochytrid Aurantiochytrium limacinum: Transcriptional reprogramming and lipid metabolism associated to their specific functions. (16th March 2020) Authors: Dellero, Younès; Maës, Cécile; Morabito, Christian; Schuler, Martin; Bournaud, Caroline; Aiese Cigliano, Riccardo; Maréchal, Eric; Amato, Alberto; Rébeillé, Fabrice Journal: Environmental microbiology Issue: Volume 22:Number 5(2020) Page Start: 1901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. (March 2014) Authors: Köhler, Jens; Schuler, Martin Journal: Future oncology Issue: Volume 10:Number 4(2014) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. (March 2014) Authors: Köhler, Jens; Schuler, Martin Journal: Future oncology Issue: Volume 10:Number 4(2014) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Issue 8 (August 2021) Authors: Subbiah, Vivek; Hu, Mimi I; Wirth, Lori J; Schuler, Martin; Mansfield, Aaron S; Curigliano, Giuseppe; Brose, Marcia S; Zhu, Viola W; Leboulleux, Sophie; Bowles, Daniel W; Baik, Christina S; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F; Lopes, Gilberto; Lin, Ch... Journal: Lancet Issue: Volume 9:Issue 8(2021) Page Start: 491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗